Rayence Co

Rayence Co Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Rayence Co (228850.KQ) as of Nov 7, 2026 is -174.33 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 317.25 % — a change of -154.95% (lower).

Cash Conversion

-174.33 %

YoY

-154.95%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Rayence Co is 2025 -174.33 % . Cash Conversion Rate (OCF/Net Income) of Rayence Co was 2024 317.25 % . It decreases by -154.95% lower compared to the previous year.

The Rayence Co Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
93.47 KRW
Jan 1, 2019
64.36 KRW
Jan 1, 2020
-1,213.83 KRW
Jan 1, 2021
144.82 KRW
Jan 1, 2022
75.32 KRW
Jan 1, 2023
131.74 KRW
Jan 1, 2024
317.25 KRW
Jan 1, 2025
-174.33 KRW
The Rayence Co Cash Conversion history
YEARCash ConversionYoY
-174.33 %-154.95%
317.25 %+140.82%
131.74 %+74.90%
75.32 %-47.99%
144.82 %-111.93%
-1,213.83 %-1,986.04%
64.36 %-31.15%
93.47 %-33.70%
141.00 %+148.46%
56.75 %-11.93%
64.44 %-70.69%
219.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rayence Co Stock analysis

What does Rayence Co do? Rayence Co., Ltd. generates revenue through the manufacturing and sale of x-ray detectors, including TFT and CMOS detectors under brand names such as 1012WCA, 17SCC/SGC, 1215CF, 1501CF, and 0712CF. The company also produces intra oral sensors branded as Ez1.0 and Ez1.5, along with mammography machines under the 1724CM and 2434CM series. These products are distributed to both domestic and international markets, serving healthcare providers and medical facilities that require diagnostic imaging equipment. The primary customers for Rayence's detectors and sensors are hospitals, clinics, and medical imaging centers seeking advanced x-ray technology. The firm's product portfolio targets the medical imaging segment, focusing on applications such as dental diagnostics with intra oral sensors and radiological imaging with mammography machines. Revenue streams are derived from direct sales of these branded products to healthcare institutions across multiple regions. Rayence's business model centers on selling specialized medical imaging equipment under its own brand names, with no mention of third-party partnerships or additional services. The company's revenue is directly tied to the purchase of its branded x-ray detectors, intra oral sensors, and mammography machines by healthcare providers who require high-quality diagnostic tools for patient care. Rayence Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rayence Co stock

Cash Conversion Rate (OCF/Net Income) of Rayence Co is -174.33 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Rayence Co changed from 317.25 % to -174.33 %, representing a -154.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Rayence Co since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Rayence Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Rayence Co

All Key Metrics — Rayence Co